including pre-procedural percent stenosis, PV pressure gradients, method of intervention, complications, and recurrence.
CONCLUSIONS These results demonstrate PVS recurrence is common, and is more likely to occur over a lengthy follow up in those who initially underwent balloon dilatation compared to stenting. Furthermore, difficult lesions where higher balloon insufflation cannot be achieved resulting in higher post-procedure PV/LA gradients are more likely to result in recurrence. Thus, PVS should be initially treated with stenting to avoid further sequelae of PVI such as recurrent PVS. BACKGROUND Optimal therapeutic strategies for patients with atrial septal defect (ASD) complicated with severe pulmonary arterial hypertension (PAH) is controversial. Combination of recent advanced PAH specific medication and transcatheter ASD closure may contribute the improvement of therapeutic outcome in these difficult patients population. Our purpose was to evaluate the efficacy of PAH-specific medications combined with transcatheter closure.
METHODS Between January 2006 and December 2013, 780 patients with ASD were performed transcatheter closure, and 48 of 780 patients (6.2%) complicated with PAH (mean pulmonary artery pressure ! 25 mm Hg). Following patients were excluded from this study because of pulmonary hypertension related to lung diseases (n¼8), left ventricular systolic dysfunction (n¼1) and pulmonary embolism (n¼1). Among 38 patients with PAH associated with ASD, 3 patients excluded because the defects was too large for device deployment. A total of 35 patients underwent successful procedures and were included in this study. Among of these, 8 patients with severe PAH required of PAH-specific medication (PAH specific group) and compared to 40 patients who did not required of PAH-specific medication (non PAH-specific group) were studied. PAH-specific medications included an endothelin receptor antagonist (bosentan; n ¼ 4), a phosphodiesterase type-5 inhibitor (sildenafil; n ¼ 4), an oral prostanoid (beraprost; n ¼ 1), and an intravenous prostanoid (epoprostenol; n ¼ 2).
RESULTS After the induction of PAH specific medication (mean 6.6 months), transcatheter ASD closure was successfully performed in all without hemodynamic intolerances. Mean device size was 26 AE 7 mm and the mean fluoroscopic time was 15 AE 8 min. Multiple devices were required in 2 patients. No hemodynamic compromise occurred in any of the patients during or after the procedure. Improvement of systolic PAP was significantly greater in PAH-specific group compared to non PAH-specific group (median, 49; range, 26 to 105 mm Hg vs. median, 14; range 4 to 77 mm Hg, respectively; p ¼ 0.0014). Among 29 patients with symptomatic heart failure, improved heart failure symptoms was observed in 21 (72%) patients with no exacerbation of heart failure. Compared with the initial evaluation, BNP levels significantly improved at follow-up at follow-up period (p ¼ 0.0017). During the mean observational period of 45 AE 25 months, one patient required hospital admission due to the progression of sick sinus syndrome. No other adverse events including hospitalization of exacerbation of PAH were observed.
CONCLUSIONS Even in patients with severe PAH, who initially did not fulfill the indication of transcatheter ASD closure, the recent PAH specific medication can contribute the significant improvement of hemodynamic condition. This treat and repair strategies may expand of therapeutic indication for transcatheter ASD closure in patients with severe PAH. BACKGROUND Transcatheter closure of large post-tricuspid shunts in patients with severe pulmonary arterial hypertension (PAH) remains a challenging clinical problem. In neonates and infants it is most often reversible, but in older patients the resolution of PAH is variable depending on the reversibility of pulmonary vascular resistance. The current study was done to assess the safety and efficacy of percutaneous device closure of large post tricuspid shunts in pediatric patients with severe PAH at short and mid term follow up.
METHODS A total of 42 pediatric patients underwent transcatheter closure of large post tricuspid shunts with severe PAH. All subjects underwent clinical examination, electrocardiography, chest x-rays and echocardiography before discharge and at 1, 6 and 12 months after the procedure and yearly thereafter for 5 years.
RESULTS Type of defect was ventricular septal defect in 8 patients (19%), patent ductus arteriosus in 27 patients (64%), aorto-pulmonary window in 5 patients (12%) and coronary cameral fistula in two patients (5%). Cardi-O-Fix VSD occluder was the most commonly used device (45%), Cardi-O-Fix PDA occluder (21%) and Amplatzer duct occlude in 17% patients. Pre-procedural pulmonary artery systolic pressure decreased significantly from mean 81.12 mmHg to mean 43.17 mmHg post procedure over a mean follow-up of 18.5 months. No residual shunt was found in 38 (90.47%) patients. Only two major complications viz; severe aortic obstruction and symptomatic complete heart block were noticed. 
